DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAMRCSGP

Allergic and non-allergic rhinitis

Essential points for quick revision.

!
Unilateral symptoms need a different assessment

Progressive one-sided obstruction with bleeding, a visible mass, facial sensory change or orbital symptoms is not adequately explained by uncomplicated rhinitis.

Action: Arrange urgent ENT assessment for suspicious unilateral disease; new visual impairment, painful eye movements or neurological features require immediate hospital assessment.

Synopsis

Distinguish allergic inflammation from irritant and medicine related nasal symptoms, select proportionate treatment, and recognise obstruction that requires investigation.

  • Itch, repeated sneezing, watery rhinorrhoea and itchy eyes linked to exposure favour allergic rhinitis.
  • Smoke, perfume, temperature change, spicy food and medicines can provoke non-allergic symptoms; mixed disease is common.
  • Ask about sleep, concentration, work exposure and asthma control rather than judging severity by nasal discharge alone.

Key red flags

Persistent unilateral bloody discharge or obstruction requires prompt examination and urgent ENT assessment for structural disease or malignancy.

Investigation priorities

01
Focused history and nasal examinationFirst step

Establish the working diagnosis before requesting allergy investigations.

Management branches

Initial careTreat a clear allergic pattern

Bilateral allergic symptoms cause persistent discomfort or impair daily activities.

  1. Agree practical trigger reduction and explain that perfect allergen avoidance is often unrealistic.
  2. Use a regularly administered intranasal corticosteroid for moderate or severe symptoms, demonstrating technique before prescribing escalation.

Key medicines

Mometasone furoate 50 micrograms per spray, NasonexFor allergic rhinitis, administer two sprays into each nostril once daily, giving 200 micrograms daily. Once controlled, reduce to one spray per nostril daily. The prescription product permits up to four sprays per nostril once daily if necessary, with subsequent reduction; reassess response and use the lowest effective maintenance dose.
Azelastine and fluticasone propionate nasal spray, DymistaFor adults and adolescents aged 12 years or over, administer one spray into each nostril twice daily. Use regularly during the period of allergen exposure, then review ongoing need and control.
Open full textbook Answer 2 questions
Sources and review status6 sources · checked 7 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom